# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹8,545 Cr** ($997M) (+11% YoY, flat QoQ) * **EBITDA:** **₹2,278 Cr** ($266M) (+5% YoY, -8% QoQ) · **Margin:** **7%** (-149 bps YoY, -243 bps QoQ) * PAT (Attributable): ₹1,419 Cr ($166M) (+2% YoY, -11% QoQ) · Margin: 16.6% * Gross Margin: 56.9% (-350 bps YoY, +134 bps QoQ) * **SG&A Expenses:** **₹2,565 Cr** ($299M) (+13% YoY, +7% QoQ) * **Free Cash Flow:** **₹433 Cr** ($51M) · **Capex:** ₹683 Cr ($80M) * **Net Cash Surplus:** **₹2,922 Cr** ($341M) as of 30 June 2025 ## B. Revenue Growth * **Resilient Top-Line Performance:** Revenue grew at a steady double-digit pace, driven by broad-based strength across markets despite softness in the US generics segment. * **Consumer Healthcare Contribution:** The consumer business was a key growth driver, with NRT and the Nestlé nutraceuticals JV contributing meaningfully to sales momentum. * **Recurring Out-Licensing Income:** **₹120 Cr** from Aurigene is not a one-time item and expected to recur in multiple quarters annually, adding stable non-core revenue. ## C. Profit Margins * **Gross Margin Pressure:** Margins declined significantly YoY due to **Lenalidomide price erosion** and lower operating leverage, partially offset by improved product mix in branded markets. * **SG&A Investment Phase:** Elevated SG&A reflected strategic investments, particularly in consumer healthcare, though core cost discipline maintained flat other SG&A YoY. * **Margin Outlook:** Full-year SG&A expected to moderate to **28–29% of sales**, while gross margins should stabilize despite Revlimid® pressure, supported by branded and diversified units. * **PSAI Margin Transient Weakness:** Low reported gross margin (2%) attributed to accounting for internal sales and overhead under-recovery; underlying API business remains healthy with recovery expected. ## D. Cash Flow * **Healthy Cash Generation:** Despite high capex, the business delivered solid free cash flow, supported by **doubling in net finance income** to ₹157 Cr. * **PLI Income Pause:** Government PLI incentives are nearly zero in FY26 after front-loaded disbursements; resumption expected in FY27–28. ## E. Balance Sheet * **Strong Liquidity & Hedging:** Maintained net cash surplus with **$2–5B financial capacity** for M&A, targeting a max **5x net debt/EBITDA**. * **Currency Risk Mitigated:** Executed hedges on **US$648M** (floor ₹13/$) and **RUB 75B** (fixed rate), reducing near-term forex volatility exposure. --- # 2. Product & Therapy Performance ## A. Key Figures * **PSAI Revenue:** **$95 Mn** Q1 FY26 (+4% YoY, -14% QoQ) * **Aurigene Pharma Services Sales:** **$17–18 Mn** Q1 FY26 · **~$100 Mn** expected FY26 revenue * **NRT Portfolio Growth:** **~12%** QoQ · accelerating from historical single-digit growth ## B. Generics Business * **PSAI Growth Trajectory:** Revenue decline in Q1 is temporary, with **double-digit growth expected for the full fiscal year** driven by 12 Drug Master Files filed and upcoming product launches. * **Lenalidomide (Revlimid®) Outlook:** Sales to remain stable in first half of FY26 but face a **sharp decline in Q3**, with minimal residual impact thereafter; pricing discipline prioritized to avoid shelf adjustments. * **C. S. Launch Pipeline:** **~20 new product launches** planned in the U.S., none highly complex, but collectively represent **upside potential** to current financial projections. ## C. Biosimilars Pipeline * **Keytruda® Biosimilar Advancement:** Strategic collaboration with **Alvotech** established for co-development and commercialization of **pembrolizumab biosimilar**, marking a key step in innovation pipeline. ## D. Consumer Healthcare * **NRT Acceleration:** Portfolio demonstrates **strong QoQ growth and structural improvement**, now outpacing historical trends with no seasonality, signaling enhanced market traction. --- # 3. Geography & Market Mix ## A. Key Figures * **North America Generics Revenue:** **$400 Mn** (–17% YoY, –4% QoQ) * **European Generics Revenue:** **€131 Mn** (+124% YoY, –6% QoQ) * **India Revenue:** **₹1,471 Cr** (+11% YoY, +13% QoQ) * **Emerging Markets Revenue:** **₹1,404 Cr** (+10% YoY, flat QoQ) ## B. North America * **Sharp Revenue Decline:** North America generics faced significant headwinds from **price erosion in Lenalidomide** and customer procurement timing, with Suboxone order shifts amplifying sequential softness. * **Pipeline Momentum:** Five recent product launches expected to drive reacceleration, signaling improving launch execution and future growth potential. ## C. Europe * **Exceptional Growth with Acquisitions:** European generics surged on the back of the NRT portfolio acquisition and 13 new launches, though pricing pressures moderated sequential performance. * **Sustainable Double-Digit Outlook:** Excluding NRT, underlying growth remains strong at **15%**, with biosimilars set to expand footprint across **ten countries**, supporting continued double-digit expansion. * **Regional Leverage:** Existing products are being leveraged beyond Europe, enhancing scale and operational efficiency. ## D. India * **Outperformance in Competitive Market:** India business grew robustly, outpacing IPM growth in both MAT and MQT terms, driven by **five new brand launches**, including high-potential assets Beyfortus™ and Sensimune™. * **Strategic Shift to Innovation:** Focus shifting from branded generics to innovative products that improve standard of care, supporting sustainable differentiation. * **Growth Ambition:** Targeting **top 5 market position** via organic expansion and licensing-in deals, backed by a **10,000-person field force**. * **Obesity Market Potential:** Semaglutide launch positions company to capture significant unmet need in India’s obesity market, though size remains qualitatively described as **big**. ## E. Emerging Markets * **Broad-Based Volume Growth:** Emerging Markets delivered solid expansion on **26 new product launches** and higher volumes, with Russia growing **17% YoY in constant currency** despite macro challenges. * **Global Semaglutide Rollout:** Strategic prioritization of semaglutide launches starting in Canada, with plans to cover **87 markets by 2026**, including India, Brazil, and Turkey post-March 2026. * **Russia as Opportunity:** No sanction-related disruptions; company maintains strong operational presence and views Russia as a strategic opportunity. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **R&D Expenditure:** ₹624 Cr ($73 Mn) (flat YoY, -14% QoQ) · **3% of sales** (-76 bps YoY, -123 bps QoQ) * **R&D Guidance:** ~**7% of sales** in current year, down from 5–9% in FY25, with flexibility between 6–8% * **Discretionary Flexibility:** **500–600 bps** of spending headroom to modulate R&D based on P&L dynamics ## B. GLP-1 Portfolio * **Strategic Focus:** R&D prioritized on **complex generics, GLP-1s, and biosimilars**, with 11 global generic filings completed this quarter, reinforcing innovation pipeline strength. * **Semaglutide Momentum:** Sema launch timelines expected to clarify soon, particularly in **Canada**, with single-digit growth forecast including H2 contributions; PAI inspection at Srikakulam may support near-term approvals. * **Liraglutide Launch Imminent:** Generic liraglutide (targeting Victoza®/Saxenda®) set for launch in **next few quarters**, aiming to be **first or among first to market**, especially for Saxenda®. * **Long-Term GLP-1 Vision:** Management views GLP-1 as a **"decade of opportunity"**, with 26 products in portfolio and focus on first-to-market execution for semaglutide and differentiated delivery. ## C. Key Biosimilar Trials * **Abatacept on Track:** Phase III readout expected **November 2025**, with IV formulation launch targeted for **end of 2026 or January 2027** in the US, followed by subcutaneous version. * **Keytruda® Biosimilar Strategy:** Development streamlined via **exemption from Phase III trials**, **Alvotech collaboration**, and **licensing**, enabling single-trial approvals across markets without replicating all indications. * **US Biosimilar Launch Pipeline:** Includes **pembrolizumab, daratumumab, and rituximab**, with rituximab to be commercialized via **Fresenius partnership**. ## D. Regulatory Submissions * **Ozempic® First, Wegovy® Later:** Initial US launch will be limited to generic **Ozempic®**, with **Wegovy® submission planned later in the year**; no anticipated regulatory hurdles for Ozempic®. * **BLA Filing Timing:** Submission planned for **December 2026 or January 2027** post-positive abatacept readout, allowing time for post-approval registrations. ## E. Innovation Focus * **Near-Term Launches Unaffected:** Despite potential future reduction in R&D to **6% of sales**, current US complex generic launches remain on track as pipelines are already filed or committed. * **Long-Term R&D Impact:** Expenditure decisions primarily influence product launches **10–12 years ahead**, ensuring strategic alignment without disrupting immediate market momentum. --- # 5. Manufacturing & Capacity ## A. Key Figures * Pen Capacity (Partner-Based): 12 Mn FY27 (~10 Mn CY2026) * **Capex:** **$80 Mn** reported · **₹2,500–2,700 Cr** expected cash outflow for the year * **Cash Balance:** **$350 Mn** ## B. Peptide Facilities * **Scaled Launch Timeline:** 2 crore pen capacity targeting FY27 (mainly CY2026), with only a small fraction of total peptide capacity allocated to this initial rollout. * **Multi-Use Clarification:** The 1 crore pen capacity for Canada refers to **multi-use pens**, each delivering a full month’s supply, correcting prior miscommunication. * **Strategic Flexibility:** New India peptide facility will support semaglutide, third-party products, and future pipeline candidates, indicating scalable and diversified design. ## C. API Supply * **Cost Competitiveness Target:** Semaglutide API expected to reach cost parity with Chinese manufacturers post-scale-up, enhancing pricing power and supply control. ## D. Partner Production * **Phased NRT Integration:** Successful integration completed in UK and Nordics; next phase includes Canada, Australia, and select Western European markets. * **CDMO Growth Focus:** Business spans small molecules and biologics, with strategic emphasis on **antibody-drug conjugates (ADCs)** and expanding R&D and commercial synergies. ## E. Capex Plans * **Near-Term Reliance on Partners:** FY26–FY27 semaglutide launches will use partner manufacturing with Dr. Reddy’s API; Vizag (FTO-11) facility contribution expected from **FY28 onward**. * **Targeted Investment Cycle:** Capex remains elevated but aligned with prior year levels, focused on peptides, biosimilars, abatacept, and GLP-1 development, funded during a period of strong internal cash flow. --- # 6. Pricing & Regulatory Risks ## A. Patent Challenges * **Headline:** No assumed patent protection for semaglutide in Canada; launch contingent on data exclusivity expiry in January '26, with **no IP barrier expected post-expiry**. * **Headline:** Indian patent litigation outcome could delay India launch by up to **two months**; a negative ruling may cause **greater-than-two-month delay in Canada** due to cross-jurisdictional impact. * **Headline:** Company remains confident in favorable resolution of Delhi High Court challenge, though details limited by sub judice restrictions. ## B. FDA Observations * **Headline:** USFDA issued Form 483s at three facilities—**Middleburgh API (2 observations)**, **Miryalaguda CTO-5 API (2)**, and **Srikakulam FTO-11 formulations (7)**—all classified as VAI with responses submitted or pending. * **Headline:** Management expects **VAI outcome to lead to validated approval**, viewing observations as addressable without material delay to commercial timelines. * **Headline:** Pricing pressure for lenalidomide seen as contained, given bulk of bookings completed despite rising competition. ## C. Pricing Strategy * **Headline:** New product pricing to be set **"as high as the market allows"**, subject to competitor dynamics and reimbursement frameworks, resulting in wide range of potential outcomes. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Outlook:** **Mid-single digit** NRT portfolio · **Flat to single-digit** US base business (FY26) * **Cost Savings Target:** **500–600 bps** reduction in discretionary R&D and SG&A costs * **Potential Cost Savings:** **₹1,500–1,800 Cr** based on current top line (~₹30,000 Cr) * 10-12 million pens (FY27) * **CDMO Growth Target:** **$250–300 Mn by 2030** ## B. Revenue Forecast * **US Base Business Stabilizing:** Expected flat to low growth in FY26, dependent on success of new product launches. * **NRT Outperforming:** Portfolio acquisition delivering above-plan performance with mid-single digit growth trajectory. ## C. Margin Targets * **Margin Expansion Hinges on Semaglutide:** Launch expected to restore EBITDA and gross margins to target levels (>25% and >50%, respectively), reversing current below-target performance. * **Discretionary Cost Rationalization:** Targeted 500–600 bps reduction in non-core spending (travel, consultants); growth investments in sales, marketing, NRT, and nutraceuticals preserved. ## D. Launch Timelines * **Semaglutide U.S. Launch Imminent:** Approval expected Oct–Nov 2025, with commercialization aligned to LOE in **early January 2026**—marking first year of major GLP-1 revenue contribution. * **Sequential Biosimilar Rollout:** Denosumab to launch ~1 year before abatacept (IV in CY2027, SC ~CY2028), enabling commercial team readiness via shared prescriber base. * **Global Pen Supply Confidence:** Management confident in selling out **2 Cr pen capacity across 80+ markets** in FY27, even without Canadian approval. ## E. Growth Assumptions * **Supply Constraints Cap Near-Term Upside:** Despite demand potential, **2x volume surge in FY27 is not feasible** due to fill-finish and device limitations; 30–40% upside possible with flexibility. * **Long-Term Growth Framework:** Anchored on four levers—base business, special products, cost optimization, and business development—with ambition to sustain **25%, 25%, double-digit growth** over time. * **R&D Investment Discipline:** Full-year spend guided to **7–5% of sales**, balancing pipeline advancement with efficiency goals.